EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • April 13th, 2018 • Vaccinex, Inc. • Pharmaceutical preparations • New York
This Exclusive License Agreement (the “Agreement”) is made effective as of the 29 day of December, 1998 (the “Effective Date”), by and between the UNIVERSITY OF ROCHESTER (“Rochester”), a New York education corporation, and VACCINEX, L.P., a for profit limited partnership organized under the laws of Georgia (“Vaccinex”).
CONFIDENTIAL GPEx®-DERIVED CELL LINE SALE AGREEMENTGpex®-Derived Cell Line Sale Agreement • April 13th, 2018 • Vaccinex, Inc. • Pharmaceutical preparations • New York
This GPEx®-Derived Cell Line Sale Agreement (this “Agreement”) is made as of this 13th day of January, 2010 (“Effective Date”), by and between Vaccinex, Inc., a Delaware corporation, with a place of business at 1895 Mt. Hope Avenue, Rochester, NY, 14620 (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company, with a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873, USA (“Catalent”).
CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENTClinical Trial Collaboration and Supply Agreement • April 13th, 2018 • Vaccinex, Inc. • Pharmaceutical preparations • New York
This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), made as of October 4, 2016 (the “Effective Date”), is by and between Ares Trading S.A., Z.I de l’Ouriettaz, CH-1170 Aubonne, Switzerland (“Merck”), and Vaccinex, Inc., having a place of business at 1895 Mt. Hope Avenue, Rochester, NY 14620 (“Vaccinex”). Merck and Vaccinex are each referred to herein individually as “Party” and collectively as “Parties”.
AMENDED AND RESTATED EXCHANGE AGREEMENTExchange Agreement • April 13th, 2018 • Vaccinex, Inc. • Pharmaceutical preparations • Delaware
WHEREAS certain of the Parties, together with VX Limited Partnership, an Ontario limited partnership (“VX LP”), VX Therapeutics Limited Partnership, a Delaware limited partnership (“VX1”), Vaccinex Products, LLC, a Delaware limited liability company (“Vaccinex Sub”), and FEZ Financial Corporation, an Ontario corporation, entered into a certain Exchange Agreement, dated as of June 18, 2012 (the “Prior Agreement”);
VACCINEX, INC. INCENTIVE STOCK OPTION AGREEMENT GRANTIncentive Stock Option Agreement • April 13th, 2018 • Vaccinex, Inc. • Pharmaceutical preparations • Delaware
This Option Agreement evidences the grant by Vaccinex, Inc. (“Vaccinex”), in accordance with the Vaccinex, Inc. 2001 Employee Equity Plan (the “Plan”), of an Incentive Stock Option (“ISO”) to (“Key Employee”) to purchase from Vaccinex shares of $0.0001 par value common stock of Vaccinex (the “Stock”) at an Option Price per share equal to $ . This ISO is granted effective as of (the “Grant Date”). Vaccinex intends that this ISO constitute an incentive stock option under § 422 of the Code.
FIRST AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • April 13th, 2018 • Vaccinex, Inc. • Pharmaceutical preparations • New York
This First Amended and Restated Investor Rights Agreement (the “Agreement”) is made and entered into as of August 22, 2003 among Vaccinex, Inc., a Delaware corporation (the “Company”), and those persons listed on Schedule A hereto.
CONFIDENTIAL GPEx® DEVELOPMENT AND MANUFACTURING AGREEMENTGpex Development and Manufacturing Agreement • April 13th, 2018 • Vaccinex, Inc. • Pharmaceutical preparations • New York
This GPEx® Development and Manufacturing Agreement (“Agreement”) is made as of January 13, 2010 (“Effective Date”), by and between Vaccinex, Inc., a with a place of business at 1895 Mt. Hope Avenue, Rochester, NY 14620, USA (“Vaccinex”) and Catalent Pharma Solutions, LLC, a Delaware limited liability company, with a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873, USA (“Catalent”).
VACCINEX, INC.Incentive Stock Option Agreement • April 13th, 2018 • Vaccinex, Inc. • Pharmaceutical preparations • Delaware
This Option Agreement evidences the grant by Vaccinex, Inc. (“Vaccinex”), in accordance with the Vaccinex, Inc. 2011 Employee Equity Plan (the “Plan”), of an Incentive Stock Option (“ISO”) to (“Key Employee”) to purchase from Vaccinex shares of $0.0001 par value common stock of Vaccinex (the “Stock”) at an Option Price per share equal to $ . This ISO is granted effective as of (the “Grant Date”). Vaccinex intends that this ISO constitute an incentive stock option under Section 422 of the Code.
